文献速递肝肾功能剂量调整

Cotadutide在2型糖尿病患者中的群体药代动力学

Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes.
PubMed 文献 · Clin Pharmacokinet · 2022-03-02

本研究基于6项临床试验中759名2型糖尿病患者的8834个血药浓度数据,建立cotadutide每日皮下注射的群体药代动力学模型。结果显示一室线性模型拟合良好,平均表观清除率1.04 L/h、表观分布容积18.7 L、吸收速率常数0.343 h⁻¹、半衰期12.9 h;体重、白蛋白、丙氨酸氨基转移酶及抗药抗体滴度对清除率有统计学显著影响但无临床意义,无需调整剂量。

要点

  • Cotadutide药代动力学符合一室线性模型,半衰期约12.9小时。
  • 体重、白蛋白、ALT及抗药抗体对清除率的影响无临床意义,无需调整剂量。
  • 基于模拟结果,cotadutide不需要按体重给药。

核心结论

  • Cotadutide药代动力学可由一室线性吸收消除模型充分描述。
  • 基于最终群体药代动力学模型的模拟,cotadutide不需要按体重给药。

研究设计与样本

  • 分析6项临床试验中759名2型糖尿病患者的8834个cotadutide血浆浓度,每日皮下注射20至600 μg。

主要发现

  • 平均表观清除率为1.04 L/h(个体间变异26.5%),表观分布容积为18.7 L(个体间变异28.7%),吸收速率常数为0.343 h⁻¹(个体间变异38.6%),半衰期为12.9 h。
  • 较高体重、较低白蛋白和较高丙氨酸氨基转移酶与cotadutide清除率增加相关,抗药抗体滴度升高与清除率降低相关。
  • 上述统计学显著效应被认为无临床意义,不需要调整剂量。
  • 年龄、性别、体重指数、糖化血红蛋白、肾功能和糖尿病病程对cotadutide药代动力学无统计学显著影响。

关键数值与推荐

  • Cotadutide平均表观清除率1.04 L/h(个体间变异26.5%)。
  • Cotadutide平均表观分布容积18.7 L(个体间变异28.7%)。
  • Cotadutide平均吸收速率常数0.343 h⁻¹(个体间变异38.6%)。
  • Cotadutide平均半衰期12.9 h。

临床怎么用

  • 临床使用cotadutide时无需根据体重、白蛋白、丙氨酸氨基转移酶或抗药抗体滴度调整剂量。
  • 无需常规按体重计算cotadutide剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Cotadutide is a balanced dual glucagon-like peptide-1/glucagon receptor agonist under development for the treatment of nonalcoholic steatohepatitis and chronic kidney disease with type 2 diabetes. The objectives of the analysis were to characterize the population pharmacokinetics of cotadutide following daily subcutaneous injection in subjects with type 2 diabetes and to evaluate the effect of demographic and clinical variables of interest on cotadutide pharmacokinetics. METHODS: This study analyzed 8834 plasma concentrations of cotadutide from 759 subjects with type 2 diabetes who received daily subcutaneous doses from 20 to 600 μg from six clinical studies. The impact of covariates on cotadutide pharmacokinetics was quantified, and body weight effect on cotadutide exposure was further evaluated using a simulation approach. The model performance was evaluated through prediction-corrected visual predictive checks. RESULTS: A one-compartment model with first-order absorption and elimination described cotadutide pharmacokinetic data well. The mean values for cotadutide apparent clearance, apparent distribution volume, absorption rate constant, and half-life were 1.04 L/h (interindividual variability [IIV]: 26.5%), 18.7 L (IIV: 28.7%), 0.343 h-1 (IIV: 38.6%), and 12.9 h, respectively. Higher body weight, lower albumin, and higher alanine aminotransferase were associated with an increase in cotadutide clearance, while an increase in anti-drug antibody titers was associated with a decrease in cotadutide clearance. These statistically significant effects were not considered clinically significant and did not warrant dose adjustment. Effects of other tested baseline covariates (age, sex, body mass index, hemoglobin A1c, renal function, duration of diabetes) were not found to statistically significantly affect cotadutide pharmacokinetics. CONCLUSIONS: Cotadutide pharmacokinetics was adequately described by a one-compartment linear model with first-order absorption and elimination. Body weight-based dosing is not necessary for cotadutide based on the simulation using the final population pharmacokinetic modeling. This model will be used to evaluate exposure-response relationships for efficacy and safety in different indications that are being studied for cotadutide.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Guan Y, Ly N, Li J, et al. Population Pharmacokinetics of Cotadutide in Subjects with Type 2 Diabetes. Clin Pharmacokinet. 2022. PMID: 35235191. doi:10.1007/s40262-021-01094-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。